A new promising influential area in modern biology and medicine is ribonucleic acid (RNA) biology. It has revolutionised molecular biology and will have profound implication for future therapies.

The Instituto de Medicina Molecular João Lobo Antunes (iMM) in Portugal will gain the support it needs to achieve scientific excellence and promote research in RNA biology. The EU-funded project RiboMed will help iMM establish a strategic collaboration via twinning with partners from already well recognised communities working on RNA biology in the University of Oxford (UK), the Weizmann Institute of Science (Israel) and The Max Delbrück Center for Molecular Medicine (MDC, Germany).

They will organise staff exchanges, experts’ visits, common works in laboratories, thematic courses, mentoring, conferences and will work towards translation of basic findings into potential novel biomarkers, RNA-based diagnostic assays and RNA therapeutic targets. This will boost the consolidation of the innovation and entrepreneurship ecosystem at iMM particularly in the field of RNA biology.

Advisory Board

The Advisory Board will closely monitor the RiboMed progress. It will include internationally recognised leaders in Medicine and RNA biology, namely Professors Detlev Ganten, Javier Caceres and Benjamin Blencowe.

Industrial Advisory Board

Melissa J. Moore
CSO mRNA research
Moderna Therapeutics

Adrian R. Krainer
St. Giles Professor of Molecular Genetics, Program Chair of Cancer and Molecular Biology
Cold Spring Harbor Laboratory and Co-Founder & Director at Stoke Therapeutics

Zandy Forbes
President & CEO

Keith Blundy
Storm Therapeutics

RiboMed Flyer here.